Suppr超能文献

利用偏振激发发射矩阵光谱法分析抗体药物偶联物合成中的蛋白质缀合反应。

Analyzing protein conjugation reactions for antibody-drug conjugate synthesis using polarized excitation emission matrix spectroscopy.

机构信息

Nanoscale BioPhotonics Laboratory, School of Chemistry, National University of Ireland, Galway, Ireland.

出版信息

Biotechnol Bioeng. 2022 Dec;119(12):3432-3446. doi: 10.1002/bit.28229. Epub 2022 Sep 28.

Abstract

Antibody-drug conjugates (ADCs) are promising anticancer therapeutics, which offer important advantages compared to more classical therapies. There are a variety of ADC critical quality attributes (CQAs) such as the protein structure, aggregation, and drug-to-antibody ratio (DAR), which all impact on potency, stability, and toxicity. Production processes can destabilize antibodies via a variety of physical and chemical stresses, and or by increased aggregation after conjugation of hydrophobic drugs. Thus, a proper control strategy for handling, production, and storage is necessary to maintain CQA levels, which requires the use of in-process quality measurements to first identify, then understand, and control the variables which adversely affect ADC CQAs during manufacturing. Here, we show how polarized excitation emission matrix (pEEM) spectroscopy, a sensitive, nondestructive, and potentially fast technique, can be used for rapidly assessing aggregation and DAR in a single measurement. pEEM provides several sources of information for protein analysis: Rayleigh scatter for identifying aggregate/particle formation and fluorescence emission to assess chemical and structural changes induced by attachment of a linker and/or a small molecule drug payload. Here, we used a nontoxic ADC mimic (monoclonal antibody with linker molecule) to demonstrate efficacy of the measurement method. Emission changes caused via light absorption by the attached linker, allowed us to predict DAR with good accuracy using fluorescence signal from the final purified products (6% relative error of prediction [REP]) and also from unpurified alkylation intermediates (11% REP). pEEM changes could also be correlated with size (hydrodynamic radius, R ) and aggregate content parameters obtained from dynamic light scattering and size exclusion chromatography (SEC). For the starting material and purified product samples, pEEM correlated better with R (R  = 0.99, 6% REP) than SEC determined aggregate content (18% REP). Combining both fluorescence and light scatter signals also enabled in-process size quantification (6% REP). Overall, combining polarized measurements with EEM and Rayleigh scatter provides a single measurement, multi-attribute test method for ADC manufacturing.

摘要

抗体药物偶联物(ADC)是一种很有前途的抗癌治疗药物,与更经典的疗法相比,它具有许多重要优势。有多种 ADC 关键质量属性(CQA),如蛋白质结构、聚集和药物抗体比(DAR),这些都影响效力、稳定性和毒性。生产工艺会通过多种物理和化学压力使抗体不稳定,或者在疏水性药物偶联后增加聚集。因此,需要采取适当的控制策略来处理、生产和储存,以维持 CQA 水平,这需要使用过程质量测量来首先识别、然后理解和控制在制造过程中对 ADC CQA 产生不利影响的变量。在这里,我们展示了偏振激发发射矩阵(pEEM)光谱学如何作为一种灵敏、非破坏性且潜在快速的技术,可用于在单次测量中快速评估聚集和 DAR。pEEM 为蛋白质分析提供了几种信息来源:瑞利散射可用于识别聚集体/颗粒形成,荧光发射可用于评估连接子和/或小分子药物有效负载连接后引起的化学和结构变化。在这里,我们使用了一种无毒的 ADC 模拟物(带有连接子的单克隆抗体)来证明该测量方法的有效性。由于附着的连接子的光吸收引起的发射变化,我们可以使用最终纯化产物的荧光信号(预测的相对误差 [REP] 为 6%)和未经纯化的烷基化中间体(REP 为 11%)准确地预测 DAR。pEEM 变化也可以与从动态光散射和尺寸排阻色谱(SEC)获得的尺寸(流体力学半径,R)和聚集含量参数相关联。对于起始材料和纯化产物样品,pEEM 与 R(R  = 0.99,REP 为 6%)的相关性优于 SEC 确定的聚集含量(REP 为 18%)。同时结合荧光和光散射信号还可以实现过程中的尺寸定量(REP 为 6%)。总体而言,将偏振测量与 EEM 和瑞利散射相结合,为 ADC 制造提供了一种单一测量、多属性测试方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3145/9828061/1eda9ea36309/BIT-119-3432-g003.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验